Shenzhen Salubris Pharmaceuticals Co., Ltd. (hereinafter referred to as “the Company”) recently received the Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA), granting permission to initiate clinical trials for the Company’s self-developed investigational drug SAL0150 tablets (project code: SAL0150) for the following indications: glycemic control in patients with type 2 diabetes, obesity or overweight, and type 2 diabetes with peripheral arterial disease and intermittent claudication[1].
SAL0150 is an oral long-acting drug developed by the Company with independent intellectual property rights. It is expected to achieve an oral dosing frequency of once weekly or less[2].
If successfully developed and approved for marketing, the drug is expected to provide more patients with a new treatment option, address unmet clinical needs, and further enrich the Company’s innovative product pipeline in the CKM chronic disease therapeutic area.
·About CKM[2]
In October 2023, the American Heart Association published a presidential advisory on cardiovascular-kidney-metabolic (CKM) syndrome, defining CKM syndrome as a health disorder resulting from the pathophysiological interplay among obesity, diabetes mellitus (DM), chronic kidney disease (CKD), cardiovascular disease (CVD), and manifesting as a systemic disease.
References:
[1] Announcement of Shenzhen Salubris Pharmaceuticals Co., Ltd. on acceptance of the clinical trial application for SAL0150
[2] Chinese Expert Consensus on Comprehensive Management of Patients with Cardiovascular-Kidney-Metabolic Syndrome
Disclaimer:
This material is intended to provide knowledge in the field of disease, enhance disease awareness, and is not for promotional purposes.
The information contained herein is for reference only. Please follow the advice or guidance of physicians or other healthcare professionals.
|About Salubris
Shenzhen Salubris Pharmaceuticals Co., Ltd., founded in 1998, is an innovation-driven pharmaceutical listed company (Stock Code: 002294) with integrated R&D, production, and marketing operations, rooted in China and serving the global market. With the mission of "providing exceptional pharmaceutical products for human health," Salubris has deepened its expertise in chronic disease treatment with a focus on cardiovascular and cerebrovascular conditions. The company has successfully commercialized alisartan monotherapy, combination drugs, and co-crystal formulations to address diverse complex hypertension challenges, establishing a unique family of first-in-class antihypertensive therapies centered on alisartan.
Salubris has established five innovative drug R&D centers and three medical device R&D bases globally, creating innovation platforms focused on small molecule drugs, biological drugs, siRNA therapeutics, gene-editing therapies, and medical devices. The company is committed to developing innovative products that address unmet clinical needs, with the goal of enhancing people's quality of life and extending healthy lifespan.
